Genmab’s market value passes $35 billion. BioPharma Dive reported on October 29 that Genmab’s shares rose to an all time high after the petosemtamab Phase 3 result covered as a full story here on October 29, adding more than $7 billion of market value to pass $35 billion, in the third consecutive positive late stage readout in a few weeks. William Blair analyst Matt Phipps wrote that the streak puts the company on a path to surpass $10 billion in annual revenue, more than offsetting the impending loss of Darzalex royalties. A Bloomberg report carried by other outlets put the Danish shares’ weekly gain at 44 percent, the largest since 2008, adding over $10 billion in a week. Sources: BioPharma Dive, October 29, 2026, and Bloomberg reporting as carried October 30, 2026.
UK Autumn Budget life sciences pledges pass £1 billion. The Chancellor’s Autumn Budget on October 29 announced over £1 billion of life sciences investments backed by almost £70 million of government grant funding, pharmaphorum and Mishcon reported: Convatec investing over £500 million over ten years in a global research and development hub in Manchester, Vertex Pharmaceuticals over £300 million in a new Oxford facility, and Kindeva £200 million in Loughborough, together expected to support more than 1,000 jobs. Endpoints News headlined the package as the UK landing £500 million in biopharma pledges, which corresponds to the Convatec commitment, the largest single item. Sources: pharmaphorum and Mishcon de Reya, October 29, 2026.
Teva to close Fairfield, New Jersey plant, 61 jobs. Teva will close its underutilized Fairfield manufacturing facility at the end of January 2027, with 61 employees to be laid off by February 1, 2027 under a state WARN filing, Fierce Pharma reported on October 27, with NJBIZ reporting the same filing and company statement. Teva said declining demand and price erosion had undermined the site’s viability despite efforts to raise production, and that its Parsippany headquarters and Edison packaging sites remain open. The closure sits inside Teva’s wider programme targeting about $700 million of savings by 2027. Sources: Fierce Pharma, October 27, 2026, and NJBIZ, October 2026.
Vertex povetacicept infection scrutiny ahead of November 30 decision. STAT reported on October 29 that Vertex’s kidney disease drug povetacicept is being scrutinized for infection risk ahead of its FDA action date. The published Phase 3 RAINIER data, released by Vertex on October 23 in the New England Journal of Medicine, showed infections in 46 percent of povetacicept patients against 41 percent on placebo, with serious or severe infections in 1 percent of each group, no opportunistic infections and no discontinuations due to infections, and proteinuria reduced 52.0 percent against 4.3 percent at week 36. The PDUFA date for accelerated approval in IgA nephropathy is November 30, 2026. The STAT item is single sourced in this run. Sources: STAT, October 29, 2026, and Vertex Pharmaceuticals via Business Wire, October 23, 2026.
MHRA Class 2 recall of Accord lercanidipine batch. The UK regulator issued a Class 2 medicines recall, reference EL(26)A/45, for one batch of Accord-UK lercanidipine hydrochloride 10 mg film coated tablets, batch M2510877, after a carton was found containing a blister strip of the 20 mg strength. The recall is at pharmacy and wholesaler level, the regulator assessed the likelihood and patient risk as low, and 20 mg remains within the authorised dose range. Class 2 recalls require action within 48 hours. Source: UK MHRA, via GOV.UK, October 29, 2026.
Lilly cash pay channel emphasis. Endpoints News reported on October 29, following Lilly’s third quarter results covered here the same day, that cash pay sales are key for the company in the United States and increasingly abroad. It is earnings call colour on the direct to consumer channel rather than a new financial disclosure, and is single sourced in this run. Source: Endpoints News, October 29, 2026.
Federal judge rejects Medicaid frailty definition. STAT reported on October 29 that a federal judge rejected the administration’s new definition of medical frailty used to limit exemptions from Medicaid work requirements. It is a ruling on eligibility administration rather than a drug pricing or approval decision, and its practical effect depends on the government’s response. Source: STAT, October 29, 2026.
FDA and CMS AI sandbox friction. STAT reported on October 30 that federal regulators are scrambling to avoid a regulatory logjam as more states move to test artificial intelligence in clinical settings through sandbox programmes that run into federal rules. No federal decision was reported in this window. Source: STAT, October 30, 2026.
Setara launches with $90 million for the pipeline Jazz left behind. Setara Biosciences announced on October 30 the completion of a $90 million Series A financing, in a company formed following the closing of Jazz Pharmaceuticals’ acquisition of Actio Biosciences, which Jazz bought for its lead programme ABS-1230 in KCNT1 related epilepsy, in a deal offering up to $1.3 billion including $820 million upfront. Setara, led by Actio founder David Goldstein, takes Actio’s remaining pipeline, headed by STAR-0871, a clinical stage oral TRPV4 inhibitor formerly called ABS-0871, for Charcot-Marie-Tooth disease type 2C and overactive bladder, with a Phase 1b patient study in CMT2C planned for 2027 and a Phase 2a in overactive bladder also planned, plus earlier discovery programmes in genetic epilepsies and migraine. The syndicate was Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital and Regeneron Ventures, with Jazz joining as a new shareholder as part of the acquisition. The item arrived as a single source flag in the final gap check and was corroborated before use by the company’s own release and two independent trade reports. Sources: Setara Biosciences via Business Wire, BioSpace and Fierce Biotech, October 30, 2026.
Not repeated: BioGeometry’s Series A extension above $100 million and Flagship’s Etcelera merger were both carried in this beat’s October 29 roundup and add no new development today, despite appearing in the gap file’s single source list. Anthropic’s biopharma research update of October 29 restates its Mithril Medicine acquisition and partner results, which this site covered on October 28. Ono’s trial failures and the Molecular Partners layoffs in the same Endpoints roundup as the LENZ item were not verified to primary sources in this run and are not carried.